Cognitive dysfunction and dementia in Parkinson disease

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Movement Disorders

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/mds.21677PMID 18175397
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic and Statistical Manual of Mental Disorders

  2008cited by this paper
• The neuropsychology of Parkinson's disease.

  2007cited by this paper
• Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia

  2006cited by this paper
• Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study.

  2005cited by this paper
• Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia

  2005cited by this paper
• Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.

  2005cited by this paper
• Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study

  2005cited by this paper
• A systematic review of prevalence studies of dementia in Parkinson's disease

  2005cited by this paper
• Cognitive status correlates with neuropathologic stage in Parkinson disease

  2005cited by this paper
• Cognitive Predictors of Dementia in Parkinson’s Disease: A Community-Based, 4-Year Longitudinal Study

  2005cited by this paper
• The national service framework for long term conditions: a novel approach for a “new style” NSF

  2005cited by this paper
• Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia

  2004cited by this paper
• Dementia in Parkinson's disease: cause and treatment

  2004cited by this paper
• Rivastigmine for dementia associated with Parkinson's disease.

  2004cited by this paper
• Cognitive and behavioral dysfunction in Parkinson’s disease: neurochemical and clinicopathological contributions

  2004cited by this paper
• Cognitive dysfunction and dementia in Parkinson’s disease

  2004cited by this paper
• Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom

  2004cited by this paper
• Psychiatric aspects of Parkinson’s disease

  2004cited by this paper
• Evidence for Impaired Encoding and Retrieval Memory Profiles in Parkinson Disease

  2004cited by this paper
• Quetiapine and Clozapine in Parkinsonian Patients With Dopaminergic Psychosis

  2004cited by this paper
• The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study.

  2004cited by this paper
• The rate of cognitive decline in Parkinson disease.

  2004cited by this paper
• Deficit of verb generation in nondemented patients with Parkinson's disease

  2003cited by this paper
• Neuropsychological Profile of Patients with Parkinson’s Disease without Dementia

  2003cited by this paper
• Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients.

  2003cited by this paper
• Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri

  2003cited by this paper
• Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

  2003cited by this paper
• Dopamine and cognitive function

  2003cited by this paper
• What causes mental dysfunction in Parkinson's disease?

  2003cited by this paper
• Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

  2003cited by this paper
• Lewy body cortical involvement may not always predict dementia in Parkinson’s disease

  2003cited by this paper
• Olanzapine treatment for dopaminergic‐induced hallucinations

  2002cited by this paper
• Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease

  2002cited by this paper
• Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

  2002cited by this paper
• Memory and executive function impairment predict dementia in Parkinson's disease

  2002cited by this paper
• Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response.

  2002cited by this paper
• Atypical Antipsychotics in Parkinson-Sensitive Populations

  2002cited by this paper
• The association of incident dementia with mortality in PD

  2002cited by this paper
• Combined effect of age and severity on the risk of dementia in Parkinson's disease

  2002cited by this paper
• Development of daytime somnolence over time in Parkinson’s disease

  2002cited by this paper
• Fluctuations in attention

  2002cited by this paper
• β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease

  2001cited by this paper
• Choline acetyltransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment

  2001cited by this paper
• Risk of dementia in Parkinson’s disease

  2001cited by this paper
• Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease

  2001cited by this paper
• beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.

  2001cited by this paper
• A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia

  2001cited by this paper
• Cognitive and vestibulo-proprioceptive components of spatial ability in Parkinson's disease.

  2000cited by this paper
• Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study

  2000cited by this paper
• A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease

  2000cited by this paper
• Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease

  2000cited by this paper
• Motor impairment in PD

  2000cited by this paper
• Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two‐year follow‐up study of previously untreated patients

  2000cited by this paper
• Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

  2000cited by this paper
• Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease

  2000cited by this paper
• Mental symptoms in Parkinson's disease are important contributors to caregiver distress

  1999cited by this paper
• Verbal memory in non-demented patients with idiopathic Parkinson's disease.

  1999cited by this paper
• Excessive daytime sleepiness and sleep benefit in Parkinson's disease: A community‐based study

  1999cited by this paper
• Clozapine for drug-induced psychosis in Parkinson's disease.

  1999cited by this paper
• Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease.

  1999cited by this paper
• Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group.

  1999cited by this paper
• Neuropsychological prediction of dementia in Parkinson’s disease

  1998cited by this paper
• Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients

  1998cited by this paper
• Cognitive impairment in Parkinson's disease

  1998cited by this paper
• Treatment of behavioural disturbances in Parkinson's disease.

  1997cited by this paper
• The occurrence of depression in Parkinson's disease. A community-based study.

  1996cited by this paper
• Cognitive deficits in Parkinson’s disease

  1996cited by this paper
• 'Lewy body disease': clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia.

  1995cited by this paper
• Neuropsychological characteristics of preclinical dementia in Parkinson's disease

  1995cited by this paper
• The neuropsychology of Parkinson's disease.

  1995cited by this paper
• Dopaminergic effects on cognitive performance in patients with Parkinson's disease.

  1995cited by this paper
• The frequency and associated risk factors for dementia in patients with Parkinson's disease.

  1995cited by this paper
• Diffuse neurofibrillary tangles with calcification: a new presenile dementia.

  1994cited by this paper
• Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases.

  1993cited by this paper
• Albendazole therapy for giant subarachnoid cysticerci.

  1993cited by this paper
• Antecedent clinical features associated with dementia in Parkinson's disease

  1993cited by this paper
• Comparison of cognitive changes in patients with Alzheimer's and Parkinson's disease.

  1993cited by this paper
• Verbal fluency deficits in Parkinson's disease.

  1993cited by this paper
• A clinicopathologic study of 100 cases of Parkinson's disease.

  1993cited by this paper
• Visuospatial impairment in Parkinson's disease

  1991cited by this paper
• Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability.

  1991cited by this paper
• [Cognitive impairment in Parkinson's disease].

  1991cited by this paper
• Normal release from proactive interference in untreated patients with Parkinson's disease.

  1991cited by this paper
• Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease.

  1991cited by this paper
• Cognitive change following MPTP exposure

  1990cited by this paper
• Memory and learning in early Parkinson's disease: evidence for a "frontal lobe syndrome".

  1990cited by this paper
• Cognitive function in Parkinson's disease: from description to theory.

  1990cited by this paper
• Cognitive impairments associated with early Parkinson's disease

  1989cited by this paper
• Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra

  1989cited by this paper
• Neuropsychological differences between the dementias of Alzheimer's and Parkinson's diseases.

  1989cited by this paper
• Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow.

  1986cited by this paper
• Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

  1985cited by this paper
• Basal forebrain neurons in the dementia of Parkinson disease

  1983cited by this paper
• Cognitive deficits in the early stages of Parkinson's disease.

  1983cited by this paper
• Cortical cholinergic deficit in mentally impaired Parkinsonian patients.

  1983cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Review Dementia Associated with Parkinson's Disease Panel 1. Risk Factors for Dementia in Patients with Pd

  year unknowncited by this paper

• Cerebellar contributions to cognitive deterioration in Parkinson's disease: Insights from multi-omics and longitudinal data.

  2026cites this paper
• Neuroprotective role of ranolazine in Parkinson disease: Drosophila melanogaster model

  2025cites this paper
• An appraisal at a glance of metallome and disease biomarkers.

  2025cites this paper
• Redefining Non-Motor Symptoms in Parkinson’s Disease

  2025cites this paper
• Efficacy of Combined Herbal and Western Medicine Based on Traditional Chinese Medicine for Mild Cognitive Impairment and Dementia in Parkinson’s Disease: A Systematic Review and Meta-Analysis

  2025cites this paper
• Transcranial Random Noise Stimulation over the Dorsolateral Prefrontal Cortex in Patients with Parkinson’s Disease and Mild Cognitive Impairment: A Pilot Study

  2025cites this paper
• Inflachromene ameliorates Parkinson's disease by targeting Nrf2-binding Keap1

  2024cites this paper
• Evaluation of binding mechanism of dietary phytochemical, capsaicin, with human transferrin: targeting neurodegenerative diseases therapeutics

  2024cites this paper
• A Delphi Panel of People With Parkinson's Disease Regarding Responsibility: Toward a Preliminary Taxonomy.

  2024cites this paper
• Sensitivity of Clock Drawing Test Alone to Screen for Cognitive Impairment in Patients with Parkinson's Disease

  2024cites this paper
• Diffusion and structural MRI as potential biomarkers in people with Parkinson’s disease and cognitive impairment

  2023cites this paper
• Sex differences in Parkinson disease-associated episodic memory and processing speed deficits

  2023cites this paper
• Investigating molecular interactions between human transferrin and resveratrol through a unified experimental and computational approach: Role of natural compounds in Alzheimer’s disease therapeutics

  2023cites this paper
• Benefits of Tango Therapy in Alleviating the Motor and Non-Motor Symptoms of Parkinson’s Disease Patients—A Narrative Review

  2022cites this paper
• Prediction of Cognitive Degeneration in Parkinson’s Disease Patients Using a Machine Learning Method

  2022cites this paper
• Animal models of action control and cognitive dysfunction in Parkinson's disease.

  2022cites this paper
• Characterization of altered molecular mechanisms in Parkinson’s disease through cell type-resolved multi-omics analyses

  2022cites this paper
• Motor–Cognitive Treadmill Training With Virtual Reality in Parkinson’s Disease: The Effect of Training Duration

  2022cites this paper
• 2 CHANGES IN MEMORY AND METACOGNITION IN OLDER ADULTHOOD

  2022cites this paper
• Toxic Metal -Mediated Neurodegradation: A Focus on Glutathione and GST Gene Variants.

  2022cites this paper
• Neuropsychological spectrum in early PD: insights from controlled and automatic behavioural regulation.

  2021cites this paper
• Expression Levels of an Alpha-Synuclein Transcript in Blood May Distinguish between Early Dementia with Lewy Bodies and Parkinson’s Disease

  2021cites this paper
• Plasma total tau predicts executive dysfunction in Parkinson's disease

  2021cites this paper
• A Detailed Biological Approach on Hormonal Imbalance Causing Depression in Critical Periods (Postpartum, Postmenopausal and Perimenopausal Depression) in Adult Women

  2021cites this paper
• Language Impairments in Dementia: From Word-Finding Difficulties to Everyday Conversation in a Dementia-Friendly Community

  2021cites this paper
• Alternative platelet activation pathways and their role in neurodegenerative diseases.

  2021cites this paper
• Pragmatic abilities in early Parkinson's disease.

  2021cites this paper
• Aging in the Human Species

  2021cites this paper
• Better Together: How Machine Learning Can Help Clinicians Determine If My Father Will Develop Parkinson Disease Dementia.

  2021cites this paper
• Parkinson's disease

  2021cites this paper
• EXPERMENTAL MODELS FOR MEMORY IMPAIRMENT

  2021cites this paper
• Event-related potential changes due to early-onset Parkinson's disease in parkin (PARK2) gene mutation carriers and non-carriers.

  2020cites this paper
• Heavy Metals Exposure and Alzheimer’s Disease and Related Dementias

  2020cites this paper
• Modelling the neuroanatomical progression of Alzheimer's disease and posterior cortical atrophy

  2020cites this paper
• Deep Feature Extraction From the Vocal Vectors Using Sparse Autoencoders for Parkinson’s Classification

  2020cites this paper
• Sex specific cognitive differences in Parkinson disease

  2020cites this paper
• A Comparative Study of the Behavioral Profile of the Behavioral Variant of Frontotemporal Dementia and Parkinson's Disease Dementia

  2020cites this paper
• The effect of chronic neuropeptide-S treatment on non-motor parameters in experimental model of Parkinson’s disease

  2020cites this paper
• Cognitive Impairment in Parkinson’s Disease: What We Know so Far

  2020cites this paper
• Balance Rehabilitation System for Parkinson's Disease Patients based on Augmented Reality

  2020cites this paper
• Two Cases of Parkinson’s Disease for Which Dental Treatment Was Effective

  2020cites this paper
• Parkinson’s Dementia

  2020cites this paper
• Parkinson’s Disease

  2020cites this paper
• Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease

  2020cites this paper
• Mouvements anormaux et psychiatrie

  2019cites this paper
• Cognitive Load Affects Speech Motor Performance Differently in Older and Younger Adults.

  2019cites this paper
• The Locus coeruleus in Parkinson’s disease - from basic research to new translational perspectives -

  2019cites this paper
• Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool.

  2019cites this paper
• Aging for Perennial Cells

  2019cites this paper
• Movement Disorders with Dementia in Older Adults

  2019cites this paper
• Performance at the clock drawing test of individuals affected by Parkinson’s disease and healthy subjects: a retrospective study

  2019cites this paper
• Noradrenergic dysfunction accelerates LPS-elicited inflammation-related ascending sequential neurodegeneration and deficits in non-motor/motor functions.

  2019cites this paper
• Marmosets in Neurologic Disease Research

  2019cites this paper
• Systematic Review on Emotion Recognition by Facial Expression and Prosody Speech in Patients with Parkinson ' s Disease

  2019cites this paper
• Attenuated NoGo-related beta desynchronisation and synchronisation in Parkinson’s disease revealed by magnetoencephalographic recording

  2019cites this paper
• Mesencephalic and extramesencephalic dopaminergic systems in Parkinson’s disease

  2019cites this paper
• Shedding light on depressive, anxiety and sleep disorders in Parkinson's disease

  2019cites this paper
• Visuospatial functioning is associated with sleep disturbance and hallucinations in nondemented patients with Parkinson’s disease

  2019cites this paper
• Parkinson’s disorder: definitions, contexts, neural correlates, strategies and clinical approaches

  2019cites this paper
• Neurochemicals, Behaviours and Psychiatric Perspectives of Neurological Diseases

  2018influential citation
• The effectiveness of a community-based exercise and educational programme on depression in Greek population with Parkinson's disease

  2018cites this paper
• Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease

  2018cites this paper
• Awareness and current knowledge of Parkinson’s disease: a neurodegenerative disorder

  2018cites this paper
• Familial aggregation of Parkinson’s disease and coaggregation with neuropsychiatric diseases: a population-based cohort study

  2018cites this paper
• Prevalence of Nonmotor Symptoms in Parkinson’s Disease

  2018cites this paper
• Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer’s Disease, and Parkinson’s Disease

  2018cites this paper
• Alternative Splicing of Alpha- and Beta-Synuclein Genes Plays Differential Roles in Synucleinopathies

  2018cites this paper
• Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study

  2018cites this paper
• Effects of physical exercise programs on cognitive function in Parkinson’s disease patients: A systematic review of randomized controlled trials of the last 10 years

  2018cites this paper
• Hospitalization characteristics of Parkinson’s Disease inpatients in the United States: a nationwide analysis

  2018cites this paper
• The Effect Of The Dopamine Agonist Pramipexole On Measures Of Impulsivity In Young, Healthy Participants

  2017cites this paper
• Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments

  2017cites this paper
• Paradigm and Aging of Perennial Neurons

  2017cites this paper
• Predictors of anxiety in early-stage Parkinson's disease - Results from the first two years of a prospective cohort study.

  2017cites this paper
• rs3851179 Polymorphism at 5′ to the PICALM Gene is Associated with Alzheimer and Parkinson Diseases in Brazilian Population

  2017cites this paper
• Prevalence and Predisposing Factors of Parkinson Disease: A Community-Based Study In Barangay Mangilag Sur, Candelaria, Quezon: A Research Protocol

  2017cites this paper
• Investigating Design Implications Towards a Social Robot as a Memory Trainer

  2017cites this paper
• Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology.

  2017cites this paper
• DEPRESSION IN PATIENTS WITH PARKINSON'S DISEASE WITH DEMENTIA

  2017cites this paper
• The Cholinergic System Modulates Memory and Hippocampal Plasticity via Its Interactions with Non-Neuronal Cells

  2017cites this paper
• An Efficient Diagnosis System for Parkinson's Disease Using Deep Belief Network

  2017cites this paper
• Detection of freezing of gait and gait initiation failure in people with Parkinson's disease using electroencephalogram signals

  2017cites this paper
• Développement d'un modèle murin de la maladie de Parkinson par augmentation compensatoire de l'arborisation axonale dopaminergique-nigrostriée

  2017cites this paper
• P300 Wave Changes in Patients with Parkinson’s Disease

  2016cites this paper
• Abnormal Echogenicity of the Substantia Nigra, Raphe Nuclei, and Third-Ventricle Width as Markers of Cognitive Impairment in Parkinsonian Disorders: A Cross-Sectional Study

  2016cites this paper
• Toxin-Induced Experimental Models of Learning and Memory Impairment

  2016cites this paper
• Different Clinical and Neuroimaging Characteristics in Early Stage Parkinson’s Disease with Dementia and Dementia with Lewy Bodies

  2016cites this paper
• Understanding the temporal dynamics of visual hallucinations in Parkinson's Disease with dementia

  2016cites this paper
• CSF biomarkers in neurodegenerative and vascular dementias.

  2016cites this paper
• Perceptions of people living with Parkinson's disease: a qualitative study in Iran.

  2016cites this paper
• Levels of cerebrospinal fluid-synuclein oligomers are increased in Parkinson ' s disease with dementia and dementia with Lewy bodies compared to Alzheimer ' s disease

  2016influential citation
• Alterations in conflict monitoring are related to functional connectivity in Parkinson's disease.

  2016cites this paper
• Hippocampal α‐synuclein and interneurons in Parkinson's disease: Data from human and mouse models

  2016influential citation
• Utility of Boston Qualitative Scoring System for Rey-Osterrieth Complex Figure: evidence from a Parkinson’s Diseases sample

  2016cites this paper
• Modified serpinA1 as risk marker for Parkinson’s disease dementia: Analysis of baseline data

  2016cites this paper
• Deep brain stimulation exacerbates hypokinetic dysarthria in a rat model of Parkinson's disease

  2016cites this paper
• Levels of cerebrospinal fluid-synuclein oligomers are increased in Parkinson ' s disease with dementia and dementia with Lewy bodies compared to Alzheimer ' s disease

  2016influential citation
• Pharmacogenetics of Non-Motor Symptoms in Parkinson's Disease

  2016cites this paper
• Aging of perennial cells and organ parts according to the programmed aging paradigm

  2016cites this paper
• Cognitive Training in Parkinson's Disease: A Review of Studies from 2000 to 2014

  2016cites this paper